CO5160323A1 - Formulaciones farmaceuticas mejoradas vir en combinacion con otros inhibidores de proteasa vih - Google Patents

Formulaciones farmaceuticas mejoradas vir en combinacion con otros inhibidores de proteasa vih

Info

Publication number
CO5160323A1
CO5160323A1 CO00040645A CO00040645A CO5160323A1 CO 5160323 A1 CO5160323 A1 CO 5160323A1 CO 00040645 A CO00040645 A CO 00040645A CO 00040645 A CO00040645 A CO 00040645A CO 5160323 A1 CO5160323 A1 CO 5160323A1
Authority
CO
Colombia
Prior art keywords
hiv protease
combination
vir
pharmaceutical formulations
protease inhibitors
Prior art date
Application number
CO00040645A
Other languages
English (en)
Inventor
A Al-Razzak Laman
Ghosh Soumojeet
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23269615&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5160323(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of CO5160323A1 publication Critical patent/CO5160323A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición farmacéutica la cual es una solución que contiene :(a) un compuesto inhibidor de proteasa VIH o una combinación de compuestos inhibidores de proteasa VIH, o las sales resultantes farmacéuticamente aceptables;(b) un solvente orgánico farmacéuticamente aceptable quecontiene un ácido graso de cadena larga seleccionado de ácidos carboxílicos C12 a C18 saturados, mono- o di- no saturados; o una mezcla de dichos ácidos grasos de cadena larga y etanol;(c) agua; y(d) opcionalmente un surfactante farmacéuticamente aceptable.
CO00040645A 1999-06-04 2000-05-31 Formulaciones farmaceuticas mejoradas vir en combinacion con otros inhibidores de proteasa vih CO5160323A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32582699A 1999-06-04 1999-06-04

Publications (1)

Publication Number Publication Date
CO5160323A1 true CO5160323A1 (es) 2002-05-30

Family

ID=23269615

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00040645A CO5160323A1 (es) 1999-06-04 2000-05-31 Formulaciones farmaceuticas mejoradas vir en combinacion con otros inhibidores de proteasa vih

Country Status (33)

Country Link
EP (2) EP1733725B2 (es)
JP (1) JP4753511B2 (es)
KR (1) KR100815412B1 (es)
CN (2) CN100418527C (es)
AR (2) AR032586A1 (es)
AT (2) ATE429224T1 (es)
AU (1) AU778198B2 (es)
BG (1) BG65445B1 (es)
BR (1) BR0007294A (es)
CA (1) CA2371109C (es)
CL (1) CL2008003491A1 (es)
CO (1) CO5160323A1 (es)
CY (2) CY1105237T1 (es)
CZ (1) CZ301308B6 (es)
DE (2) DE60042092D1 (es)
DK (2) DK1733725T4 (es)
ES (2) ES2265946T3 (es)
HK (1) HK1045804A1 (es)
HU (1) HU229501B1 (es)
IL (3) IL146025A0 (es)
MX (1) MXPA01012478A (es)
MY (1) MY127908A (es)
NO (1) NO328968B1 (es)
NZ (1) NZ515016A (es)
PL (1) PL197671B1 (es)
PT (2) PT1183026E (es)
SA (1) SA00210237B1 (es)
SI (2) SI1183026T1 (es)
SK (2) SK286305B6 (es)
TR (1) TR200103488T2 (es)
TW (1) TWI244390B (es)
WO (1) WO2000074677A2 (es)
ZA (1) ZA200108641B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY145265A (en) * 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
US7141593B1 (en) 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
DE60042092D1 (de) * 1999-06-04 2009-06-04 Abbott Lab Arzneizubereitungen enthaltend mindestens einen HIV Preoteaseinhibitor
ATE329579T1 (de) 1999-11-12 2006-07-15 Abbott Lab Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
ES2676151T3 (es) * 2000-01-19 2018-07-17 Abbvie Inc. Formulaciones farmacéuticas mejoradas
WO2002096395A1 (en) * 2001-05-25 2002-12-05 Abbott Laboratories Soft elastic capsules comprising ritonavir and/or lopinavir
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
KR20160074018A (ko) * 2005-12-30 2016-06-27 길리애드 사이언시즈, 인코포레이티드 Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법
RS54237B9 (sr) * 2006-07-07 2019-07-31 Gilead Sciences Inc Modulatori farmakokinetičkih svojstava terapeutika
AU2013204805C1 (en) * 2006-07-07 2017-03-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
AU2015258296B2 (en) * 2006-07-07 2017-08-17 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
NO345893B1 (no) * 2006-07-07 2021-09-27 Gilead Sciences Inc Modulatorer av farmakokinetikkegenskaper til terapeutika
AU2015234299B2 (en) * 2006-07-07 2017-03-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
CA2669938C (en) 2006-11-15 2016-01-05 Abbott Laboratories Solid pharmaceutical dosage formulations
AR065439A1 (es) * 2007-02-23 2009-06-10 Gilead Sciences Inc Derivados de tiazoles 1,3 no condensados,composiciones farmaceuticas que los contienen y usos como agentes antivirales, en particular anti hiv.
AU2015204378B2 (en) * 2007-02-23 2017-03-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
AU2013204817B2 (en) * 2007-02-23 2015-05-07 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
ME02631B (me) 2007-02-23 2017-06-20 Gilead Sciences Inc Modulatori farmakokinetičkih svojstava lijekova
TWI448457B (zh) * 2007-07-06 2014-08-11 Gilead Sciences Inc 治療劑的藥物動力學性質之調節劑
ES2555209T3 (es) 2008-01-04 2015-12-29 Gilead Sciences, Inc. Inhibidores del citocromo P450
UA108738C2 (uk) * 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
IL110752A (en) † 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) † 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
DE69535127T2 (de) * 1994-03-18 2007-02-15 Supernus Pharmaceuticals, Inc. Emulgierte arzneistoffabgabesysteme
DE4431489A1 (de) * 1994-09-03 1996-03-07 Heidelberger Baustofftech Gmbh Schnellhärtende aminosilanvernetzende Silikonmassen
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
EP0876353A1 (en) * 1995-12-13 1998-11-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
MY145265A (en) * 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
DE60042092D1 (de) * 1999-06-04 2009-06-04 Abbott Lab Arzneizubereitungen enthaltend mindestens einen HIV Preoteaseinhibitor

Also Published As

Publication number Publication date
TWI244390B (en) 2005-12-01
CA2371109C (en) 2011-04-26
SI1733725T1 (sl) 2009-08-31
EP1733725B2 (en) 2012-08-08
DE60042092D1 (de) 2009-06-04
DK1733725T4 (da) 2012-09-17
HUP0201591A3 (en) 2002-10-28
EP1733725A1 (en) 2006-12-20
JP2003501386A (ja) 2003-01-14
SA00210237B1 (ar) 2006-11-07
MXPA01012478A (es) 2003-10-14
ATE429224T1 (de) 2009-05-15
NO328968B1 (no) 2010-06-28
BR0007294A (pt) 2002-08-27
SI1733725T2 (sl) 2012-10-30
DK1733725T3 (da) 2009-08-03
NO20015670L (no) 2001-11-20
AR032586A1 (es) 2003-11-19
AU5287700A (en) 2000-12-28
WO2000074677A3 (en) 2001-02-22
AU778198B2 (en) 2004-11-25
CZ301308B6 (cs) 2010-01-06
ZA200108641B (en) 2003-01-20
CZ20014293A3 (cs) 2002-03-13
IL216686A (en) 2014-01-30
DE60029219D1 (de) 2006-08-17
DE60029219T2 (de) 2007-06-28
SK286305B6 (en) 2008-07-07
ES2265946T3 (es) 2007-03-01
CN100418527C (zh) 2008-09-17
PT1733725E (pt) 2009-06-30
SI1183026T1 (sl) 2006-10-31
HK1045804A1 (en) 2002-12-13
EP1733725B1 (en) 2009-04-22
KR100815412B1 (ko) 2008-03-20
ES2324549T5 (es) 2012-10-31
CN101361723B (zh) 2013-11-06
EP1183026A2 (en) 2002-03-06
EP1183026B1 (en) 2006-07-05
IL146025A0 (en) 2002-07-25
AR064309A2 (es) 2009-03-25
TR200103488T2 (tr) 2002-04-22
CN1353607A (zh) 2002-06-12
SK287185B6 (sk) 2010-02-08
CY1105237T1 (el) 2010-03-03
NO20015670D0 (no) 2001-11-20
CY1109135T1 (el) 2014-07-02
IL146025A (en) 2012-04-30
HU229501B1 (hu) 2014-01-28
MY127908A (en) 2006-12-29
ATE332132T1 (de) 2006-07-15
SK17202001A3 (sk) 2002-03-05
NZ515016A (en) 2004-02-27
KR20020011994A (ko) 2002-02-09
PT1183026E (pt) 2006-11-30
HUP0201591A2 (en) 2002-09-28
CL2008003491A1 (es) 2009-03-06
BG106239A (en) 2002-08-30
PL351943A1 (en) 2003-07-14
IL216686A0 (en) 2012-01-31
DK1183026T3 (da) 2006-11-06
CN101361723A (zh) 2009-02-11
PL197671B1 (pl) 2008-04-30
BG65445B1 (bg) 2008-08-29
CA2371109A1 (en) 2000-12-14
WO2000074677A2 (en) 2000-12-14
ES2324549T3 (es) 2009-08-10
JP4753511B2 (ja) 2011-08-24

Similar Documents

Publication Publication Date Title
CO5160323A1 (es) Formulaciones farmaceuticas mejoradas vir en combinacion con otros inhibidores de proteasa vih
AR010634A1 (es) Composicion farmaceutica en forma de una solucion para la administracion de inhibidores de proteasa hiv
ES2195798T1 (es) Formulacion para mujeres menopausicas.
EA200100895A1 (ru) Незаменимые жирные кислоты для предотвращения сердечно-сосудистых приступов
AR100291A2 (es) Composición catártica
AR109354A2 (es) Una composición que comprende un compuesto bicíclico y compuesto
ES2045106T3 (es) Composiciones de blanqueo.
PE20040549A1 (es) Composiciones para remover manchas de superficies dentales y metodos de fabricacion y uso de ellas
UY28897A1 (es) Ácido 2-((2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil)amino)-3-(fenilpiridin-2-ilamino)propiónico sustancialmente puro como inhibidor de la cinasa ikb
PE20100363A1 (es) Composiciones que comprenden nucleosidos
DE60217103D1 (de) Verstärkte wirkung mehrfach ungesättigter fettsäuren
PE20000565A1 (es) Jarabe antihistaminico estabilizado
CO5261563A1 (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco
ES2122520T3 (es) Composicion de limpieza con dos partes que comprende al menos un compuesto de peroxido.
ES2721148T3 (es) Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel y métodos relacionados de preparación y uso
AR079399A2 (es) Procedimientos para preparar bifenazato
TWI256288B (en) Liquid formulations
ITMI20022627A1 (it) Uso di una miscela di esteri di acidi grassi come combustibile
CL2009001680A1 (es) Composiciones agroquimicas que comprenden a)metconazol o una sal del mismo y b)un acido carboxilico alifatico de cadena lineal o ramificada, saturado o no saturado y donde la relacion molar de (b) respecto de (a) es superior a 1
AR044864A1 (es) Composiciones orales antiplaca acuosas estables
PL371670A1 (en) Improvements in or relating to liquid detergent compositions
AR032455A1 (es) Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
ECSP003680A (es) Proceso para derivados del acido fenilacetico
ES2104387T3 (es) Mejoras relativas a pastillas de jabon.
BG66112B1 (bg) Подобрени фармацевтични състави